BOSTON--(BUSINESS WIRE)--March 14, 2006--Point Therapeutics, Inc. (NASDAQ: POTP) today reported financial results for the fourth quarter and fiscal year ended December 31, 2005. Point reported a net loss of $5,899,000 or $0.22 per share, compared with a net loss of $4,721,000, or $0.26 per share, in the fourth quarter of 2004. For fiscal year 2005, Point reported a net loss of $22,674,000 or $0.98 per share compared with a net loss of $15,158,000 or $0.87 per share for fiscal year 2004. Revenues of $161,000 were recorded in the fourth quarter of 2005 resulting from a $600,000 Orphan Products Development grant which is funding a portion of Point’s current Phase 2 study combining talabostat with rituximab in advanced chronic lymphocytic leukemia (CLL).
